IRIS
ROSSETTI, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.569
NA - Nord America 5.244
AS - Asia 2.536
SA - Sud America 456
Continente sconosciuto - Info sul continente non disponibili 248
AF - Africa 173
OC - Oceania 20
Totale 14.246
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.122
IT - Italia 1.407
RU - Federazione Russa 1.109
GB - Regno Unito 959
SG - Singapore 761
CN - Cina 617
IE - Irlanda 603
VN - Vietnam 381
BR - Brasile 366
SE - Svezia 308
FR - Francia 299
DE - Germania 287
HK - Hong Kong 242
UA - Ucraina 157
FI - Finlandia 140
IN - India 101
BD - Bangladesh 93
ZA - Sudafrica 84
NL - Olanda 76
CA - Canada 70
ES - Italia 60
KR - Corea 48
IR - Iran 45
PL - Polonia 40
TR - Turchia 38
MX - Messico 31
IQ - Iraq 28
PK - Pakistan 27
AR - Argentina 25
AT - Austria 22
CZ - Repubblica Ceca 20
JP - Giappone 20
PH - Filippine 18
AU - Australia 15
BE - Belgio 15
CO - Colombia 15
NG - Nigeria 15
CI - Costa d'Avorio 13
EG - Egitto 13
VE - Venezuela 13
CH - Svizzera 12
ID - Indonesia 12
EC - Ecuador 11
KE - Kenya 11
MA - Marocco 10
CL - Cile 9
KZ - Kazakistan 9
SA - Arabia Saudita 9
AE - Emirati Arabi Uniti 8
DK - Danimarca 8
LT - Lituania 8
NP - Nepal 8
UZ - Uzbekistan 8
IL - Israele 7
JO - Giordania 6
PT - Portogallo 6
PY - Paraguay 6
CY - Cipro 5
ET - Etiopia 5
JM - Giamaica 5
LV - Lettonia 5
MY - Malesia 5
PE - Perù 5
SK - Slovacchia (Repubblica Slovacca) 5
AZ - Azerbaigian 4
DZ - Algeria 4
EU - Europa 4
KG - Kirghizistan 4
LK - Sri Lanka 4
MN - Mongolia 4
PS - Palestinian Territory 4
SN - Senegal 4
TH - Thailandia 4
UY - Uruguay 4
BY - Bielorussia 3
DO - Repubblica Dominicana 3
GE - Georgia 3
LB - Libano 3
NZ - Nuova Zelanda 3
QA - Qatar 3
RO - Romania 3
TT - Trinidad e Tobago 3
AO - Angola 2
BG - Bulgaria 2
BS - Bahamas 2
BW - Botswana 2
CG - Congo 2
CR - Costa Rica 2
EE - Estonia 2
HR - Croazia 2
IM - Isola di Man 2
LU - Lussemburgo 2
NO - Norvegia 2
OM - Oman 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BJ - Benin 1
BN - Brunei Darussalam 1
Totale 13.980
Salva come PNG Salva come JPEG
Città #
Dallas 867
Southend 770
Dublin 587
Singapore 437
Ashburn 411
Chandler 326
Moscow 323
Fairfield 309
Santa Clara 258
San Jose 255
Milan 235
Hong Kong 214
Beijing 204
Siena 169
Council Bluffs 147
Menlo Park 146
Seattle 122
Rome 121
Woodbridge 121
Ho Chi Minh City 116
Jacksonville 114
Cambridge 111
Ann Arbor 108
Houston 105
Wilmington 102
Munich 99
Los Angeles 94
New York 93
Princeton 91
Hanoi 78
Helsinki 74
Johannesburg 74
Florence 67
Lauterbourg 67
Dong Ket 55
Hefei 52
The Dalles 50
Nanjing 46
Orem 46
Seoul 43
São Paulo 41
Buffalo 38
Chicago 37
Málaga 37
Boardman 34
London 30
Turku 30
Shanghai 27
Warsaw 26
Dearborn 24
Frankfurt am Main 24
Nuremberg 24
Chennai 23
San Mateo 23
Columbus 22
San Diego 22
Montreal 19
Denver 18
Nottingham 18
Stockholm 18
Brescia 17
Catania 17
Lappeenranta 17
Toronto 17
Da Nang 16
Tehran 16
Fremont 15
Naples 15
Perugia 15
Phoenix 15
Tokyo 15
Atlanta 14
Izmir 14
Redondo Beach 14
Rio de Janeiro 14
Turin 14
Abidjan 13
Abuja 13
Amsterdam 13
Brussels 13
Karaj 13
Paris 13
Vienna 13
Athens 12
Baghdad 12
Brooklyn 12
Düsseldorf 12
Haiphong 12
Bengaluru 11
Boston 11
Figino 11
Lancaster 11
Mumbai 11
Portsmouth 11
Prague 11
Washington 11
Comun Nuovo 10
Guangzhou 10
Horsham 10
San Francisco 10
Totale 8.766
Salva come PNG Salva come JPEG
Nome #
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 592
Staphylococcus aureus vaccine preclinical and clinical development: current state of the art 588
Genetic mechanisms of critical illness in COVID-19 452
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 440
An explainable model of host genetic interactions linked to COVID-19 severity 386
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 369
Antirheumatic agents in covid-19: is IL-6 the right target? 368
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 352
Mapping the human genetic architecture of COVID-19 325
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 319
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 313
Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 306
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 303
HCMV infection in renal transplant recipients: a retrospective cohort study 290
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 289
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV 286
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 281
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 279
Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments 270
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 270
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 263
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 260
Serial KL-6 measurements in COVID-19 patients 253
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 251
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 250
Un caso di “insolita” spondilodiscite da Staphylococcus capitis 243
Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients 238
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 232
Use of Miltefosine in a Patient With Mucosal Leishmaniasis and HIV-coinfection: A Challenge in Long-Term Management 226
FALLIMENTO VIROLOGICO PRECOCE CON SELEZIONE RAPIDA DI FARMACORESISTENZA IN UN PAZIENTE CON HCV GENOTIPO 1, TRATTATO CON PEGINTERFERON, RIBAVIRINA E TELAPREVIR 219
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 218
MIASI CAVITARIA A LOCALIZZAZIONE NASALE DA OESTRUS OVIS: UN CASO CLINICO 215
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 215
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 205
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: A multi-cohort study 196
Which screening for Leishmania infantum in asymptomatic blood donors? 187
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 184
Discordant liver fibrosis predictors in virologically suppressed people living with hiv without hepatitis virus infection 184
Il ruolo dell'infezione da CMV e del suo monitoraggio attivo nella nuova era dei trapianti di rene: risultati di una coorte completa 182
Gestione clinica di effetti collaterali multipli in un paziente con epatite cronica da HCV in trattamento con terapia triplice comprendente telaprevir 182
Infezione da Mycobacterium marinum: le difficoltà diagnostiche e terapeutiche di un caso raro 179
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 177
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: Results from a European multi-cohort study 173
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 172
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 167
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe 162
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 151
Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019 140
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV 137
Laboratory diagnosis of Mycoplasma pneumoniae infections: data analysis from clinical practice 133
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort 131
The Uprise of Human Leishmaniasis in Tuscany, Central Italy: Clinical and Epidemiological Data from a Multicenter Study 118
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 117
Hepatitis C epidemiology and treatment outcomes in Italy: Impact of the DAA era and the COVID‐19 pandemic 114
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies 113
Predictors of Virological Failure Among People Living with HIV Switching from an Effective First-Line Antiretroviral Regimen 110
Cohort Profile: A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network) 98
Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial 94
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 89
Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients 83
Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study 83
null 14
Durability of Long‐Acting Cabotegravir + Rilpivirine in Virologically Suppressed Adults Living With HIV: A Multicenter Observational Cohort in Tuscany (LAHIV) 10
Totale 14.246
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.862
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.862
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022893 0 94 45 95 46 36 53 51 76 89 104 204
2022/20231.308 61 141 162 133 98 216 76 126 122 72 61 40
2023/20241.262 43 48 110 76 70 297 347 59 10 52 56 94
2024/20252.102 84 94 277 131 272 153 123 112 184 103 209 360
2025/20265.489 331 637 720 700 1.165 182 582 159 206 279 209 319
2026/2027303 198 105 0 0 0 0 0 0 0 0 0 0
Totale 14.246